Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RRM2 | P31350 | 9/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | RRM1 | P23921 | 1/20 | 0.50 |
| ▸ | RRM2B | Q7LG56 | 1/20 | 0.50 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.50 |
| ▸ | CTH | P32929 | 1/20 | 0.47 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.46 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31753656 | 1.00 | RRM2 (0.67) | RRM2KDM4ERRM1RRM2BCISD1 | |
| SCHEMBL7749775 | 1.00 | RRM2 (0.67) | RRM2KDM4ERRM1RRM2BCISD1 | |
| SCHEMBL783293 | 0.84 | RRM2 (0.67) | RRM2KDM4ERRM1RRM2BCISD1 | |
| SCHEMBL29420113 | 0.84 | RRM2 (0.67) | RRM2KDM4ERRM1RRM2BCISD1 | |
| SCHEMBL30094126 | 0.84 | RRM2 (0.67) | RRM2KDM4ERRM1RRM2BCISD1 | |
| SCHEMBL783292 | 0.84 | RRM2 (0.67) | RRM2KDM4ERRM1RRM2BCISD1 | |
| SCHEMBL8685653 | 0.77 | MAPT (0.64) | RRM2KDM4E | |
| SCHEMBL6261110 | 0.76 | RRM2 (0.71) | RRM2KDM4ECTHNCOA1NCOA3 | |
| SCHEMBL6261112 | 0.76 | RRM2 (0.71) | RRM2KDM4ECTHNCOA1NCOA3 | |
| SCHEMBL534248 | 0.75 | TOP2A (0.68) | RRM2RRM1RRM2BCISD1CTH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5721259-A | Method of using 2-formylpyridine thiosemicarbazone compounds | YALE UNIVERSITY (US) | 1998-02-24 | — | — | US | claimed |
| EP-0570294-B1 | 2-Formylpyridine thiosemicarbazone derivatives, their preparation and their use as antitumor agents | UNIV YALE (US) | 1997-07-30 | — | — | EP | claimed |
| US-5281715-A | 2-formylpyridine thiosemicarbazone compounds | YALE UNIVERSITY (US) | 1994-01-25 | — | — | US | claimed |
| EP-0570294-A1 | 2-Formylpyridine thiosemicarbazone derivatives, their preparation and their use as antitumor agents | YALE UNIVERSITY (US) | 1993-11-18 | — | — | EP | claimed |
| CN-101302192-B | Prodrug forms of ribonucleotide reductase inhibitors 3-AP and 3-AMP | VION PHARMACEUTICALS INC | 2014-01-22 | — | — | CN | disclosed |
| US-20090298891-A1 | Methods of Treating or Preventing Cancer Using Pyridine Carboxaldehyde Pyridine Thiosemicarbazone Radiosensitizing Agents | GOVERNMENT OF THE US, AS REPRESENTED BY THE SECRETADY OF HEALTH AND HUMAN SERVICES (US) | 2009-12-03 | — | — | US | disclosed |
| CN-101302192-A | Prodrug forms of ribonucleotide reductase inhibitors 3-AP and 3-AMP | VION PHARMACEUTICALS INC (US) | 2008-11-12 | — | — | CN | disclosed |
| EP-1951230-A2 | METHODS OF TREATING OR PREVENTING CANCER USING PYRIDINE CARBOXALDEHYDE PYRIDINE THIOSEMICARBAZONE RADIOSENSITIZING AGENTS | Government of the United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007035489-A2 | METHODS OF TREATING OR PREVENTING CANCER USING PYRIDINE CARBOXALDEHYDE PYRIDINE THIOSEMICARBAZONE RADIOSENSITIZING AGENTS | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-03-29 | — | — | WO | disclosed |
| CN-1117733-C | Process for synthesis of ribonucleotide reductase inhibitors 3-AP and 3-AMP | VION PHARMACEUTICALS INC (US) | 2003-08-13 | — | — | CN | disclosed |
| EP-0984932-A4 | PROCESS FOR THE SYNTHESIS OF RIBONUCLEOTIDE REDUCTASE INHIBITORS 3-AP AND 3-AMP | VION PHARMACEUTICALS INC (US) | 2001-04-04 | — | — | EP | disclosed |
| EP-0988285-A4 | PRODRUG FORMS OF RIBONUCLEOTIDE REDUCTASE INHIBITORS 3-AP AND 3-AMP | VION PHARMACEUTICALS INC (US) | 2000-08-16 | — | — | EP | disclosed |
| US-5869676-A | Process for the synthesis of ribonucleotide reductase inhibitors 3-AP and 3-AMP | VION PHARMACEUTICALS, INC. (US) | 1999-02-09 | — | — | US | disclosed |
| WO-1998051670-A1 | PROCESS FOR THE SYNTHESIS OF RIBONUCLEOTIDE REDUCTASE INHIBITORS 3-AP AND 3-AMP | VION PHARMACEUTICALS, INC. (US) | 1998-11-19 | — | — | WO | disclosed |
| WO-1998051669-A1 | PRODRUG FORMS OF RIBONUCLEOTIDE REDUCTASE INHIBITORS 3-AP AND 3-AMP | VION PHARMACEUTICALS, INC. (US) | 1998-11-19 | — | — | WO | disclosed |
| US-5767134-A | Prodrug forms of ribonucleotide reductase inhibitors 3-AP and 3-AMP | VION PHARMACEUTICALS, INC. (US) | 1998-06-16 | — | — | US | disclosed |
| US-5721259-A | Method of using 2-formylpyridine thiosemicarbazone compounds | YALE UNIVERSITY (US) | 1998-02-24 | — | — | US | disclosed |
| EP-0570294-B1 | 2-Formylpyridine thiosemicarbazone derivatives, their preparation and their use as antitumor agents | UNIV YALE (US) | 1997-07-30 | — | — | EP | disclosed |
| US-5281715-A | 2-formylpyridine thiosemicarbazone compounds | YALE UNIVERSITY (US) | 1994-01-25 | — | — | US | disclosed |
| EP-0570294-A1 | 2-Formylpyridine thiosemicarbazone derivatives, their preparation and their use as antitumor agents | YALE UNIVERSITY (US) | 1993-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298891-A1 | Methods of Treating or Preventing Cancer Using Pyridine Carboxaldehyde Pyridine Thiosemicarbazone Radiosensitizing Agents | DPYD, NTPCR, RRM2B | RRM2 4/4885KDM4E 1184/4885RRM1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.